Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.408 EUR | +0.87% | +3.29% | -11.30% |
May. 07 | GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding | CI |
Apr. 05 | GenSight: financial visibility assured until the end of April | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.30% | 34.14M | |
+7.56% | 111B | |
+11.37% | 106B | |
-12.41% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-9.04% | 16.81B | |
+38.08% | 12.54B | |
-24.36% | 8.09B |
- Stock Market
- Equities
- SIGHT Stock
- News GenSight Biologics S.A.
- Gensight Biologics Pulls Marketing Authorization Application in Europe for Lumevoq Gene Therapy